EchoNous, the leader in point-of-care ultrasound innovation, proudly announces the launch of Kosmos Bladder, a groundbreaking ...

U.S. Industrial Production Growth Slowed More Than Expected in May By Investing.com - Jun 17, 2022 1 By Geoffrey Smith Investing.com -- U.S. industrial output eked out its slowest growth in five ...

NSCLC Phase 2b trial (N=86) showed a median overall survival of 14.1 months, with 15.8 months for PD-L1 negative patients. Get Wall Street's Hottest Chart Every Morning ...

(NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder ... s GMP capacity to manufacture large ...

Johnson & Johnson has initiated an application seeking Food and Drug Administration approval of its TAR-200 drug-device combination for the treatment of certain patients with bladder cancer.

Bob Dylan earns his fortieth career hit on Billboard's Americana/Folk Albums chart as Mixing Up The ... [+] Medicine / A Retrospective debuts. April 1965: American electric folk hero Bob Dylan ...

The funding will increase the capacity of these organizations to achieve their goals, build knowledge, and implement change. This includes establishing partnerships and networks, increasing community ...

If bacteria enter your urethra and your immune system does not fight them off, they may spread to your bladder and kidneys, resulting in a UTI. According to older research cited in a 2015 review ...

India logged a record high renewable energy capacity addition of about 30 GW in 2024, more than 113% higher than 13.75 GW recorded in 2023, according to the Ministry of New & Renewable Energy data.

India achieved a record high renewable energy capacity addition of around 30 GW in 2024, a significant increase from 13.75 GW in 2023. This growth is crucial for meeting the ambitious target of ...

Pfizer said a late-stage study of its sasanlimab drug candidate met its key goal in certain patients with bladder cancer. Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in ...

Pfizer's Phase 3 trial showed sasanlimab with BCG improved event-free survival in high-risk NMIBC patients. Sasanlimab's safety profile aligns with known PD-1 inhibitors and BCG data from previous ...